This inventor holds 4 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Qyuns Therapeutics Co., Ltd., Qyuns Therapeutics Co., Ltd.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Huaiyao Qiao: Innovator in Monoclonal Antibody Research
Introduction
Huaiyao Qiao is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of monoclonal antibody research, holding a total of 4 patents. His work focuses on developing innovative treatments for diseases mediated by specific proteins in the human body.
Latest Patents
Among his latest patents is the development of an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody. This invention provides a high-affinity antibody that exhibits neutralizing activity, making it a potential treatment for TSLP-mediated diseases. Another notable patent is the anti-human interleukin-33 monoclonal antibody, which also demonstrates high affinity and neutralizing activity, aimed at preventing or treating diseases related to human interleukin-33.
Career Highlights
Huaiyao Qiao is associated with Qyuns Therapeutics Co., Ltd., where he continues to advance his research and development efforts. His innovative work in monoclonal antibodies has positioned him as a key figure in therapeutic advancements.
Collaborations
He collaborates with notable colleagues such as Jiwan Qiu and Wei Chen, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Huaiyao Qiao's contributions to monoclonal antibody research are paving the way for new therapeutic options in medicine. His dedication to innovation continues to impact the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile